An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls

References

• Food and Drug Administration. Gardasil. 2015; Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042
   Google Scholar
• European Medicines Agency, Cervarix. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac05-8001d124
   Google Scholar
• European Medicines Agency; Gardasil. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
   Google Scholar
• Center for Disease Control. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). 2010; Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
   Google Scholar
• Center for Disease Control. FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP). 2015; Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm.
   Google Scholar
• European Medicines Agency, Committee for medicinal products for human use post authorization summary of positive opinion* for Gardasil 2008.
   Google Scholar
• European Medicines Agency, Summary of opinion1 (post authorisation) Cervarix. 2011.
   Google Scholar
• European Medicines Agency, Assessment report Cervarix. 2013.
   Google Scholar
• European Medicines Agency, Assessment report Gardasil 2014.
   Google Scholar
• Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2015; 11(7):1689–702; PMID:26062002; http://dx.doi.org/10.1080/21645515.2015.1050570
   PubMed Web of Science ®Google Scholar
• Food and Drug Adminstration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 2014; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm
   Google Scholar
• WHO SAGE. Evidence based recommendations on Human Papillomavirus (HPV) vaccine schedules. 2014.
   Google Scholar
• Donken R, De Melker HE, Rots NY, Berbers G, Knol MJ. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine 2015; 33(12):1426–32; PMID:25659273; http://dx.doi.org/10.1016/j.vaccine.2015.01.072
   PubMed Web of Science ®Google Scholar
• Donken R, Knol MJ, Bogaards JA, Van Der Klis FR, Meijer CJ, De Melker HE. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. J Infect 2015; 71:61–73; PMID:25709084.
   PubMed Web of Science ®Google Scholar
• European Center for Disease Control. Vaccine Schedule. 2015 Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
   Google Scholar
• Institute Catala d'Oncologica. Summary report. 2015; Available from: www.hpvcentre.com
   Google Scholar
• WHO. Immunization schedule by antigen. 2015; Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules
   Google Scholar
• Turner TB, Huh WK, HPV Vaccines: translating immunogenicity into efficacy. Hum Vaccin Immunother 2015:1–3.
   PubMed Web of Science ®Google Scholar
• Dobson SR, Mcneil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309(17):1793–802; PMID:23632723.
   PubMed Web of Science ®Google Scholar
• Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, Mcneil S, Money D, Dionne M, Palefsky J, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014; 32(5):624–30; PMID:24055350; http://dx.doi.org/10.1016/j.vaccine.2013.09.007
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, Rojas R, Herrero R, Hernandez-Avila M. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32(6):725–32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, et al. Sustained Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine Administered as a Two-Dose Schedule in Adolescent Girls: Five-Year Clinical Data and Modelling Predictions from a randomized study. Hum Vaccin Immunother. 2016 Jan 2; 12(1):20-9’’, For 47 via Science Direct’’Papillomavirus Research Volume 1, December 2015, Pages 59–73.
   Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10(5):1155–65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7(12):1374–86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6(11):1242–50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
   PubMed Web of Science ®Google Scholar
• Hernandez-Avila M, Torres L, Stanley M, Salmeron J, Cruz-Valdez A, Munoz N, Herrero R, Villasenor-Ruiz IF, Lazcano-Ponce E. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using two versus three doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother, 2016; 12(1):30-8; http://dx.doi.org/10.1080/21645515.2015.1058458
   PubMed Web of Science ®Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26(52):6844–51; PMID:18930097; http://dx.doi.org/10.1016/j.vaccine.2008.09.073
   PubMed Web of Science ®Google Scholar
• Mollers M, Vossen JM, Scherpenisse M, Van Der Klis FR, Meijer CJ, De Melker HE. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013; 85(8):1379–85; PMID:23722396; http://dx.doi.org/10.1002/jmv.23616
   PubMed Web of Science ®Google Scholar
• Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51(10):1845–53; PMID:16099939; http://dx.doi.org/10.1373/clinchem.2005.052381
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118(5):2135–45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40(6):564–71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
   PubMed Web of Science ®Google Scholar
• Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 2012; 21(9):1547–54; PMID:22752082; http://dx.doi.org/10.1158/1055-9965.EPI-12-0558
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli UR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2015.
   Web of Science ®Google Scholar
• Stanley MA, Sudenga SL, Giuliano AR, Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014; 13(8):1027–38; PMID:25001893; http://dx.doi.org/10.1586/14760584.2014.935767
   PubMed Web of Science ®Google Scholar
• Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014; 32(26):3232–6; PMID:24731816; http://dx.doi.org/10.1016/j.vaccine.2014.04.005
   PubMed Web of Science ®Google Scholar
• Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES, 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30(24):3572–9; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
   PubMed Web of Science ®Google Scholar
• Stanley M. HPV vaccines. Best Pract Res Clin Obstet Gynaecol 2006; 20(2):279–93; PMID:16356772; http://dx.doi.org/10.1016/j.bpobgyn.2005.10.011
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin 2011; 7(12):1343–58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12.18281
   PubMed Web of Science ®Google Scholar
• Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11(1):39–44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5
   PubMed Web of Science ®Google Scholar
• Smith MA, Liu B, Mcintyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015; 211(1):91–9; PMID:25117753; http://dx.doi.org/10.1093/infdis/jiu370
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Berkhof J. Assessment of herd immunity from human papillomavirus vaccination. Lancet Infect Dis 2011; 11(12):896; author reply 896–7; PMID:22115067; http://dx.doi.org/10.1016/S1473-3099(11)70324-3
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550 000 Young Girls. Clin Infect Dis 2015; 61(5):676–82; PMID:25944340; http://dx.doi.org/10.1093/cid/civ364
   PubMed Web of Science ®Google Scholar
• Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparen P, Arnheim-Dahlstrom L Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311(6):597–603; PMID:24519299; http://dx.doi.org/10.1001/jama.2014.95
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103(19):1444–51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16(7):775–86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110(11):2804–11; http://dx.doi.org/10.1038/bjc.2014.198
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Malloy M, Budd AC, Saville AM, Drennan K, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research, 2015.
   Google Scholar
• Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458; http://dx.doi.org/10.1136/bmj.g1458
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM, Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
   PubMed Web of Science ®Google Scholar
• Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111(9):1824–30; PMID:25180766; http://dx.doi.org/10.1038/bjc.2014.479
   PubMed Web of Science ®Google Scholar
• Van De Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28(33):5473–84; PMID:20573580; http://dx.doi.org/10.1016/j.vaccine.2010.05.056
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22(4):505–15; PMID:21540743; http://dx.doi.org/10.1097/EDE.0b013e31821d107b
   PubMed Web of Science ®Google Scholar
• Brisson M, Van De Velde N, Boily MC, Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect 2011; 87(1):41–3; PMID:20924049; http://dx.doi.org/10.1136/sti.2010.044412
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686):301–14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28(42):6858–67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine 2014; 32(26):3237–42; PMID:24726246; http://dx.doi.org/10.1016/j.vaccine.2014.03.098
   PubMed Web of Science ®Google Scholar
• Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015; 350:g7584; PMID:25567037; http://dx.doi.org/10.1136/bmj.g7584
   PubMed Web of Science ®Google Scholar
• Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagon T, Brisson M Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 2014; 32(44):5845–53; PMID:25131743; http://dx.doi.org/10.1016/j.vaccine.2014.07.099
   PubMed Web of Science ®Google Scholar